Yahong Pharmaceuticals announced that the company's APL-1202 oral combination of torrelenzumab as a first-line treatment for MIBC completed Phase II clinical trial and obtained a positive therapeutic signal.
亚虹医药：APL-1202与替雷利珠单抗联合治疗MIBC取得积极疗效信号
Yuhong Medicine: APL-1202 combined with Trastuzumab achieves positive therapeutic signal in the treatment of MIBC.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated